Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter.

Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up

Shares of Sanofi (EPA: SAN) gained around 1% today after the UK government agreed to buy $500 million worth of COVID-19 vaccines from Sanofi and GlaxoSmithKline (LON: GLK). Moreover, the French giant raised its 2020 earnings forecast today.

Sanofi stock price moves higher on a £500 million vaccine deal

GlaxoSmithKline

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have reached an agreement with the United Kingdom to supply up to 60 million doses of their jointly-developed coronavirus vaccine, the two drugmakers announced Wednesday.

GlaxoSmithKline, Sanofi Ink Deal With UK To Supply Up To 60M Doses of COVID-19 Vaccine

Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts.

Sanofi lifts earnings view as Regeneron stake sale boosts Q2

Britain has signed a deal for the supply of up to 60 million doses of a potential coronavirus vaccine developed by Sanofi and GlaxoSmithKline.

UK signs deal for 60m doses of potential coronavirus vaccine

 Sanofi H1 2020 business EPS  (1)   growth of 9.2%  (2)   driven by transformation

Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation

Sanofi shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Sanofi Flashes Improved Technical Strength As Big Investors Accumulate Shares appeared first on Investor's Business Daily.

Sanofi Flashes Improved Technical Strength As Big Investors Accumulate Shares

AstraZeneca

Gilead Sciences

Eli Lilly

Merck

Pfizer

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

U.S. drugmaker earnings heat up this week with spotlight on vaccine news

Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.

Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?

Johnson & Johnson

European efforts to secure potential COVID-19 vaccines from Pfizer , Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

Exclusive: EU talks with Pfizer, Sanofi, J&J on COVID vaccines hit snags - sources

AbbVie

Novartis

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

BRIDGEWATER, N.J., July 22, 2020 /PRNewswire/ -- Sanofi Pasteur, the vaccines global business unit of Sanofi, today shipped the first of its influenza vaccine doses to health care providers in the U.S.

Sanofi begins shipping flu vaccines in U.S. for 2020-2021 season

CD38KO NK cell therapy has the potential to maximize the efficacy of anti-CD38 against multiple myeloma

Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi

   nformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - June 2020

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Why Sanofi (SNY) is a Great Dividend Stock Right Now

BioNTech SE

Moderna

The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna , Sanofi and Johnson & Johnson as well as biotech firms BioNtech and CureVac, two EU sources told Reuters.

Exclusive: EU in talks with Moderna, BioNtech, CureVac to secure possible COVID vaccines

Quest Diagnostics

Labcorp Holdings Inc

Novavax

Regeneron Pharmaceuticals

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

Bristol-Myers

In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026.

Pharma Companies Look to Blockbusters to Drive Sales

Sanofi: Buy And Permanently Hold A Value Stock With A Limited Short-Term Downside

CAMBRIDGE, Mass., July 9, 2020 /PRNewswire/ -- Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with...

Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

iShares Nasdaq Biotechnology ETF

COVID-19 has been the biggest driver of the stock market this year, whether it was the crash in March or recovery that has taken place since then.

5 Speculative COVID-19 Stocks That Could Still Surge

Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.

Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study

Gritstone Oncology Inc

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Shares of Regeneron Pharmaceuticals Inc. REGN, +2.18% were down 2.4% and Sanofi's SNY, +0.68% stock declined 1.7% in after-hours trading on Friday after the companies halted a Phase 3 clinical trial testing their rheumatoid arthritis drug Kevzara as a COVID-19 treatment.

Regeneron, Sanofi halt trial for experimental coronavirus drug, shares fall

Inovio Pharmaceuticals

Royalty Pharma

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19.

News for Sanofi Stock (SNY)